Label: KETOROLAC TROMETHAMINE solution

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated March 7, 2022

If you are a consumer or patient please visit this version.

  • INDICATIONS & USAGE

    Before you use Ketorolac Tromethamine Ophthalmic solution 0.5% for the first time:

    1.Check to make sure that the tamper evident ring between the bottle and the cap is not broken ( See Figure A). If the tamper evident ring is broken or missing, contact your pharmacist.

    [Img-fig-a]

    2.Tear off the tamper evident ring ( See Figure B).

    [Img-fig-b]



    3.To open the bottle, remove the cap by turning it in the counterclockwise direction ( See Figure C).

    [Img-fig-c]

    This Instructions for Use has been approved by the U.S. Food and Drug Administration.

    Rev.10/2021

  • 88436-1 - Section Title Not Found In Database

    17.1 Slow or Delayed Healing

    Patients should be informed of the possibility that slow or delayed healing may occur while using nonsteroidal anti-inflammatory drugs (NSAIDs).

    17.2 Avoiding Contamination of the Product

    Patients should be instructed to avoid allowing the tip of the bottle to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

    Also, to avoid the potential for cross-contamination, the patient should be advised to use one bottle for each eye following bilateral ocular surgery. The use of the same bottle of topical eye drops for both eyes following bilateral ocular surgery is not recommended.

    17.3 Contact Lens Wear

    Patients should be advised that ketorolac tromethamine ophthalmic solution 0.5% should not be administered while wearing contact lenses.

    17.4 Intercurrent Ocular Conditions

    Patients should be advised that if they develop an intercurrent ocular condition (e.g., trauma or infection) or have ocular surgery, they should immediately seek their physician’s advice concerning the continued use of ketorolac tromethamine ophthalmic solution 0.5%.

    17.5 Concomitant Topical Ocular Therapy

    Patients should be advised that if more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.

    Manufactured by:

    Micro Labs Limited

    Bangalore-560099, INDIA.

    Manufactured for:

    Micro Labs USA Inc.

    Somerset, NJ 08873

    Rev.10/2021

  • HOW SUPPLIED

    Ketorolac Tromethamine Ophthalmic solution 0.5% is supplied sterile, in white opaque LDPE bottles with white opaque LDPE Nozzles with HDPE grey caps as follows.

    3 mL in 5 mL bottle NDC 42571-137-31

    5 mL in 5 mL bottle NDC 42571-137-25

    10 mL in 10 mL bottle NDC 42571-137-26

    Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

  • CLINICAL STUDIES

    Two controlled clinical studies showed that ketorolac tromethamine ophthalmic solution was significantly more effective than its vehicle in relieving ocular itching caused by seasonal allergic conjunctivitis.

    Two controlled clinical studies showed that patients treated for two weeks with ketorolac tromethamine ophthalmic solution were less likely to have measurable signs of inflammation (cell and flare) than patients treated with its vehicle.

    Results from clinical studies indicate that ketorolac tromethamine has no significant effect upon intraocular pressure; however, changes in intraocular pressure may occur following cataract surgery.

  • DESCRIPTION

    Ketorolac tromethamine ophthalmic solution 0.5% is a member of the pyrrolo-­pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use. Its chemical name is (±)-5-Benzoyl-2,3-dihydro-1H pyrrolizine-1-carboxylic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) and it has the following structure:

    Ketorolac tromethamine ophthalmic solution 0.5% is supplied as a sterile isotonic aqueous 0.5% solution, with a pH of 7.4. Ketorolac tromethamine ophthalmic solution 0.5% is a racemic mixture of R-(+) and S-(-)- ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. The pKa of ketorolac is 3.5. This white to off-white crystalline substance discolors on prolonged exposure to light. The molecular weight of ketorolac tromethamine is 376.41. The osmolality of ketorolac tromethamine ophthalmic solution 0.5% is 290 mOsmol/kg.

    Each mL of ketorolac tromethamine ophthalmic solution contains: Active: ketorolac tromethamine 0.5%. Preservative: benzalkonium chloride 0.01%. Inactives: edetate disodium 0.1%; octoxynol 40; water for injection; sodium chloride; hydrochloric acid and/or sodium hydroxide to adjust the pH.

  • INDICATIONS & USAGE

    Ketorolac tromethamine ophthalmic solution 0.5% is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution 0.5% is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.

  • PRINCIPAL DISPLAY PANEL

    fhtyfgh

  • INGREDIENTS AND APPEARANCE
    KETOROLAC TROMETHAMINE 
    ketorolac tromethamine solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:72189-335(NDC:42571-137)
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    KETOROLAC TROMETHAMINE (UNII: 4EVE5946BQ) (KETOROLAC - UNII:YZI5105V0L) KETOROLAC TROMETHAMINE5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    WATER (UNII: 059QF0KO0R)  
    BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    OCTOXYNOL-40 (UNII: 9T1C662FKS)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:72189-335-055 mL in 1 BOTTLE; Type 0: Not a Combination Product03/07/2022
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20341003/07/2022
    Labeler - Direct Rx (079254320)
    Registrant - Direct Rx (079254320)
    Establishment
    NameAddressID/FEIBusiness Operations
    Direct Rx079254320relabel(72189-335)